Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BioVie Inc. BIVI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

BioVie Inc. (BIVI) is a Biotechnology company in the Healthcare sector, currently trading at $1.41. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Valuation: BIVI trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25).

Net income is $18M (loss), growing at -3.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $349,894 against $19M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 9.1 (strong liquidity). Debt-to-assets is 1.6%. Total assets: $22M.

Analyst outlook: 5 / 5 analysts rate BIVI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

BIVI SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BIVI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
BIVI: +0%/yr revenue is, -3.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BIVI: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 9.1 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
BIVI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate BIVI as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.06-13.2
Volume85.26K
Avg Volume (30D)85.23K
Market Cap$10.63M
Beta (1Y)0.56
Share Statistics
EPS (TTM)-12.12
Shares Outstanding$1.48M
IPO Date2020-09-18
Employees14
CEOCuong Viet Do
Financial Highlights & Ratios
Gross Profit$-229.38K
EBITDA$-16.98M
Net Income$-17.54M
Operating Income$-18.07M
Total Cash$17.54M
Total Debt$349.89K
Net Debt$-17.19M
Total Assets$21.56M
Price / Earnings (P/E)-0.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS09074F5044

Price Chart

Track all markets on TradingView
BIVI
BioVie Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.06 52WK RANGE 13.20

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$17.12
+1.18%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.30
+3.13%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 MREO
MREO
Mereo BioPharma Group plc
$0.34
+2.98%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.33
+3.10%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message